Related Experiment Video

Updated: Aug 5, 2026

Isolation, Expansion, and Adipogenic Induction of CD34+CD31+ Endothelial Cells from Human Omental and Subcutaneous Adipose Tissue
10:28

Isolation, Expansion, and Adipogenic Induction of CD34+CD31+ Endothelial Cells from Human Omental and Subcutaneous Adipose Tissue

Published on: July 17, 2018

Aberrant peripheral blood CD34+ subsets as a candidate cellular biomarker for type 2 diabetes mellitus

Itsuko Miyazawa1, Junko Okano2, Natsuko Ohashi1

  • 1Department of Medicine, Shiga University of Medical Science, Japan.

Practical Laboratory Medicine
|July 28, 2026
PubMed

Insights

Researchers identified a specific type of stem cell in the blood of type 2 diabetes mellitus (T2DM) patients. This cell type, elevated in T2DM, correlates with HbA1c levels, suggesting its potential as a biomarker for diabetes management.

Area of Science:

  • Hematology
  • Immunology
  • Endocrinology

Background:

  • Standard diabetes markers like HbA1c and blood glucose (BS) lack insight into cellular pathology.
  • Previous research in animal models identified diabetes stem cells (CD106+TNFα+proinsulin+) implicated in diabetic pathology.

Purpose of the Study:

  • To investigate the presence and significance of a specific hematopoietic stem/progenitor cell subset in patients with type 2 diabetes mellitus (T2DM).
  • To determine if this cell subset correlates with glycemic control markers such as HbA1c.

Main Methods:

  • Analysis of peripheral blood samples from T2DM patients (n=12) and healthy controls (n=10).
  • Flow cytometry to quantify the proportion of CD106+, TNFα+, proinsulin+, CD34+ cells.

Main Results:

  • A significantly higher proportion of CD106+TNFα+proinsulin+CD34+ cells was observed in T2DM patients compared to healthy controls.
  • The frequency of these cells showed a significant positive correlation with HbA1c levels.

Conclusions:

  • The aberrant CD34+ cell subset in peripheral blood may serve as a candidate cellular biomarker for T2DM.
  • This biomarker is associated with chronic glycemic status in type 2 diabetes.
  • Further validation in larger patient cohorts is necessary to establish clinical utility.

Keywords:
Bone marrowCD106+ TNFα+ proinsulin+ CD34+ subsetCellular biomarkerDiabetic stem cellHbA1cType 2 diabetes mellitus

Related Concept Videos

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...